Scarica l'app Stockscreener
2.47
6.93%
0.16
Dopo l'orario di chiusura:
2.48
0.010
+0.40%
Precedente Chiudi:
$2.31
Aprire:
$2.3
Volume 24 ore:
13.47M
Relative Volume:
1.66
Capitalizzazione di mercato:
$515.36M
Reddito:
$176.23M
Utile/perdita netta:
$-257.83M
Rapporto P/E:
-1.7034
EPS:
-1.45
Flusso di cassa netto:
$-246.00M
1 W Prestazione:
+20.49%
1M Prestazione:
+26.67%
6M Prestazione:
+448.28%
1 anno Prestazione:
+581.57%
Intervallo 1D:
$2.2501
$2.53
Intervallo di 1 settimana:
$2.042
$2.84
Portata 52W:
$0.304
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Nome
Sangamo Therapeutics Inc
Settore
Industria
Telefono
(510) 970-6000
Indirizzo
501 CANAL BLVD., RICHMOND, CA
Confronta SGMO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
2.47 | 515.36M | 176.23M | -257.83M | -246.00M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Aggiornamento | Truist | Hold → Buy |
| 2024-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-01-07 | Ripresa | Guggenheim | Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-12-16 | Ripresa | H.C. Wainwright | Buy |
| 2020-09-08 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | SunTrust | Buy |
| 2019-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-10-10 | Iniziato | Guggenheim | Buy |
| 2018-06-20 | Iniziato | BofA/Merrill | Buy |
| 2017-11-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2016-11-01 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-10-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-10-23 | Ripresa | Jefferies | Buy |
| 2013-05-03 | Iniziato | BioLogic Equity Research | Sell |
| 2011-02-23 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-07-29 | Reiterato | Wedbush | Outperform |
| 2009-10-19 | Iniziato | Brean Murray | Sell |
| 2009-10-07 | Reiterato | Leerink Swann | Outperform |
| 2009-08-25 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
Astellas and Sangamo sign capsid deal for neurological diseases - MSN
Astellas partners with Sangamo on cutting-edge gene therapy - The Pharma Letter
Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development (NASDAQ:SGMO) - Seeking Alpha
Sangamo and Astellas link up in a $1.32B AAV deal - BioWorld Online
HC Wainwright Reiterates Buy Rating for Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Shares Gap UpHere's What Happened - MarketBeat
Sangamo stock gains on Astellas licensing deal (SGMO:NASDAQ) - Seeking Alpha
Sangamo inks $20M gene therapy deal with Astellas; shares rally - Investing.com
Sangamo Shares Rally Premarket on License Deal With Astellas - MarketWatch
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Astellas hopes Sangamo's capsid can get gene therapies across the blood-brain barrier - FirstWord Pharma
Regarding Sangamo - substack.com
Sangamo Therapeutics, Inc. and Astellas Pharma Inc. Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases - Marketscreener.com
Sangamo Therapeutics Lands Major $1.3B Gene Therapy Deal with Astellas for Brain Disease Treatment - StockTitan
Sangamo Therapeutics (NASDAQ:SGMO) Shares Down 5%Time to Sell? - MarketBeat
Sangamo surges 24% after Roche ends development of hemophilia A gene therapy - MSN
Sangamo Therapeutics (NASDAQ:SGMO) Shares Gap DownShould You Sell? - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Upgraded by StockNews.com - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Trading Up 25.5%Still a Buy? - MarketBeat
Sangamo shares surge on Roche gene therapy withdrawal By Investing.com - Investing.com Canada
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces hurdles - Investing.com
Sangamo Therapeutics (NASDAQ:SGMO) Upgraded to "Buy" at Truist Financial - MarketBeat
The Analyst Landscape: 6 Takes On Sangamo Therapeutics - Benzinga
Sangamo Biosciences’ Legal Victory and Hemophilia Trial Success - TipRanks
Jacobs Levy Equity Management Inc. Lowers Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.
Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30% - Simply Wall St
Sangamo Therapeutics (NASDAQ:SGMO) Downgraded to Hold Rating by StockNews.com - MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Wasatch Advisors LP - MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat
GSA Capital Partners LLP Sells 587,544 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat
Sangamo stock climbs 12% post-market on FDA update for ST-503 - MSN
Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts - Simply Wall St
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - BioSpace
Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment - Marketscreener.com
Sangamo's Novel Gene Therapy for Chronic Pain Gets FDA Clearance for Clinical Trials | SGMO Stock News - StockTitan
What is HC Wainwright's Forecast for SGMO FY2024 Earnings? - MarketBeat
FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada
Sangamo: Q3 Earnings Snapshot - Marketscreener.com
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN
Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com India
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Sangamo Therapeutics Inc Azioni (SGMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):